chylomicron


Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to chylomicron: Chylomicron Retention Disease
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to chylomicron

a microscopic particle of triglycerides produced in the intestines during digestion

References in periodicals archive ?
The effect of dietary fat load on the size and composition of chylomicrons in thoracic duct lymph.
5] Nonstandard abbreviations: T2DM, type 2 diabetes mellitus; TC, total cholesterol; LDL-C, LDL cholesterol; apo B, apolipoprotein B; HBL, hypobetalipoproteinemia; ABL, abetalipoproteinemia; CMRD, chylomicron retention disease; FHBL, familial HBL; MGUS, monoclonal gammopathy of undetermined significance.
LPL deficiency causes massive accumulation of chylomicrons in plasma.
Cholesterol is transported in plasma mainly by low-density lipoproteins (LDL) and chylomicron remnants.
A specific measurement of chylomicrons and a large VLDL might explain the time effect.
This publication provides additional, independent support on the ability of Glybera to restore chylomicron metabolism in LPLD patients.
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance.
This results in the accumulation of lipid droplets in the intestine and the liver, due to an inability to produce chylomicrons and VLDL in the intestine and liver, respectively.
The main compositional difference between VLDL remnants and chylomicron remnants is the presence of apo B 100 as the major protein of VLDL remnants, rather than apo B48, and the lower relative triglyceride concentration.
Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway.
From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment.
Postprandial lipids and their associated partially hydrolyzed chylomicron remnants appear to promote early atherogenesis, adversely affect endothelial function, associate with atherogenic small LDL particles, and correlate with both prothrombotic and proinflammatory biomarkers, including factor VII, plasminogen activator inhibitor-1, and C-reactive protein (4).
AMSTERDAM, May 20, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Later this month we will present additional data at ASGCT regarding improved chylomicron handling, which we believe could be used in the future by physicians as a biomarker for Glybera in LPLD patients.